Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Biogen Inc    BIIB

BIOGEN INC (BIIB)

Delayed Quote. Delayed  - 08/26 10:00:00 pm
308.17 USD   +0.43%
08/09DJBIOGEN : Plans to Name Hemophilia Spinoff 'Bioverativ'
08/09 BIOGEN : Announces Bioverativ as Name of New Hemophilia-Focused Comp..
08/09DJBotox Maker Allergan's Revenue Climbs, but Loss More Than Doubles..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Biogen Idec Inc. : Biogen 4th-Quarter Profit Falls 2.7% on Higher Costs; Revenue Up

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/28/2013 | 01:13pm CEST
   By Tess Stynes and Melodie Warner 
 

Biogen Idec Inc.'s (BIIB) fourth-quarter earnings fell 2.7% as the biotechnology company's efforts to bulk up its product pipeline masked its revenue growth.

The company also forecast 2013 adjusted earnings of $7.15 to $7.25 a share on about 10% revenue growth. Analysts surveyed by Thomson Reuters expect $7.27 a share on a 9% rise in revenue to $5.98 billion.

Biogen on Thursday said a new version of its blockbuster multiple-sclerosis drug Avonex was successful in a late-stage trial, strengthening the company's stable of drugs for the degenerative nerve disease. However, the overall market for such injectable drugs is expected to decline sharply amid a growing market for oral-pill-based drugs. Biogen's own BG-12 pill could be approved and launched in the U.S. as soon as March.

Biogen has been beefing up its sales force and readying its manufacturing supply chain as some drugs in its late-stage product pipeline have been drawing closer to entering the market.

Research and development costs rose 1.8% in the latest period while selling, general and administrative costs jumped 32%.

Biogen reported a profit of $292.1 million, or $1.23 a share, down from $300.2 million, or $1.22 a share, a year earlier. Excluding items such as stock-option expense, amortization and restructuring charges, per-share earnings fell to $1.40 from $1.51. Revenue increased 6.9% to $1.42 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.46 a share on revenue of $1.39 billion.

In the latest quarter, sales of Avonex rose 7.1% to $753.2 million.

Shares closed Friday at $146.20 and were inactive premarket. The stock is up 23% over the past year.

Write to Tess Stynes at tess.stynes@dowjones.com and Melodie Warner at melodie.warner@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BIOGEN INC
08/09DJBIOGEN : Plans to Name Hemophilia Spinoff 'Bioverativ'
08/09 BIOGEN : Announces Bioverativ as Name of New Hemophilia-Focused Company
08/09DJBotox Maker Allergan's Revenue Climbs, but Loss More Than Doubles -- WSJ
08/08DJAllergan Revenue Increases, Though Loss Widens--Update
08/04 BIOGEN : Enigma Biomedical Group Inc Signs Research Agreement with Biogen and Me..
08/04 AMYRIS : Enters Partnership with Biogen to Develop Alternative Cell Lines Suppor..
08/02DJBiogen Draws Takeover Interest from Rival Drugmakers--2nd Update
08/02DJBiogen Draws Takeover Interest from Rival Drugmakers--2nd Update
08/02DJBiogen Draws Takeover Interest from Rival Drugmakers--Update
08/02DJBiogen Draws Takeover Interest from Rival Drugmakers
More news
Sector news : Specialty & Advanced Pharmaceuticals
03:22p Stada shareholder AOC pushes through board reshuffle
12:43a ABBOTT LABORATORIES : Whiplashed investors stay skittish about St. Jude
08/26DJST JUDE MEDICAL : . Jude Denies Claims in Muddy Waters Report
08/26 MUDDY WATERS SAYS ST. JUDE SHARES CO : Cnbc
08/26DJALERE : Sues Abbott to Force Merger -- 2nd Update
More sector news : Specialty & Advanced Pharmaceuticals
News from SeekingAlpha
08/26 Biogen Holds On To Lingo, And Pivotal Data For Nanobiotix
08/26 Don't Fear The Fed - Cramer's Mad Money (8/25/16)
08/25 Siponimod Rides To Novartis' Rescue
08/24 Candidate Clinton's harsh comments on high price of Mylan's EpiPen sends biot..
08/22 Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2016 Update
Advertisement
Financials ($)
Sales 2016 11 474 M
EBIT 2016 5 915 M
Net income 2016 4 015 M
Finance 2016 1 436 M
Yield 2016 -
P/E ratio 2016 16,87
P/E ratio 2017 15,65
EV / Sales 2016 5,76x
EV / Sales 2017 5,60x
Capitalization 67 526 M
More Financials
Chart BIOGEN INC
Duration : Period :
Biogen Inc Technical Analysis Chart | BIIB | US09062X1037 | 4-Traders
Full-screen chart
Technical analysis trends BIOGEN INC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 340 $
Spread / Average Target 10%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
George A. Scangos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Alfred W. Sandrock Chief Medical Officer & Executive Vice President
Spyridon Artavanis-Tsakonas Chief Scientific Officer & Executive VP
Adriana Karaboutis Executive VP-Technology & Business Solutions
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN INC0.59%67 526
ABBVIE INC9.06%105 220
MERCK KGAA8.23%13 807
KYOWA HAKKO KIRIN CO L..-24.83%8 104
MALLINCKRODT PLC0.39%8 070
JAZZ PHARMACEUTICALS P..-8.57%7 780
More Results